Status: Recruiting
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
This study is being conducted to explore the immunological mechanism of action of Peptide-coated Conditionally Replicating Adenovirus-1 (PeptiCRAd-1) plus Checkpoint inhibitor (CPI) therapy in multiple cancer types, as well as to obtain early information on the safety of this combination therapy.
Participants needed: 15
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Valo Therapeutics OyUpdated: May 12, 2026Locations: 7
Eligibility criteria
Written informed consent. [+20]
Receipt of any oncolytic virus treatment, or administration of a vaccine contain... [+19]